Treatment of advanced thymoma and thymic carcinoma

Current Treatment Options in Oncology

Volumn 9, Issue 4-6, 2008, Pages 277-287

  Rajan, Arun ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; METHYLPREDNISOLONE; MITOMYCIN; NAVELBINE; OCTREOTIDE; PACLITAXEL; PEMETREXED; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; PARANEOPLASTIC SYNDROME; RECURRENCE RISK; REVIEW; SURVIVAL TIME; THYMECTOMY; THYMIC CARCINOMA; THYMOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; AGED; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; SURVIVOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; SURVIVORS; THYMECTOMY; THYMOMA; THYMUS NEOPLASMS;

EID: 70249086627     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-009-0083-7     Document Type: Review

References (52)

1. Fornasiero A, Daniele O, Ghiotto C et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990; 8(8): 1419-1423.
2. Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg 2003; 125(2): 434-467. doi: 10.1067/mtc.2003.133.
3. Johnson SB, Eng TY, Giaccone G, Thomas CR. Thymoma: Update for the new millennium. The Oncologist 2001; 6: 239-246. doi: 10.1634/ theoncologist.6-3-239.
4. Masaoka A, Mondem Y, Nakahara K, et al.: Follow-up study of thymoma with special reference to their clinical stages. Cancer 1981; 48: 2485-92. doi: 10.1002/ 1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R
5. Masaoka A, Yamakawa Y, Niwa H, et al. Thymectomy and malignancy. Eur J Cardiothoracic Surg 1994; 8: 251-253. doi: 10.1016/1010-7940(94)90155-4.
6. Okumura M, Onta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: A clinical study of 273 patients. Cancer 2002; 94: 624-32. doi: 10.1002/cncr.10226.
7. Suster S, Moran CA. Histologic classification of thymoma: The World Health Organization and beyond. Hematol Oncol Clin N Am 2008;22:381-392. doi: 10.1016/j.hoc.2008.03.001.
8. Lopez-Cano M, Ponseti-Bosch JM, Espin-Basany E, et al. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg 2003; 76: 1643-1649. doi: 10.1016/ S0003-4975(03)01139-1.
9. Morgenthaler TI, Brown LR, Colby TV, et al. Thymoma. Mayo Clin Proc 1993; 68: 1110-1123.
10. Suadjian JV, Enriquez P, Siverstein MN, et al. The spectrum of diseases associated with thymoma: Coincidence or syndrome? Arch Intern Med 1974; 134: 374-379. doi: 10.1001/archinte.134.2.374.
11. Tormoehlen LM, Pascuzzi RM. Thymoma, myastenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008;22(3):509-526. doi: 10.1016/j.hoc.2008.03.004.
12. Wright CD. Management of Thymomas. Critical Reviews in Oncology/ Hematology 2008; 65: 109-120. doi: 10.1016/j.critrevonc.2007.04.005.
13. Kondo K, Monden Y. Therapy for thymic epithelial tumors: A clinical study of 1320 patients from Japan. Ann Thorac Surg 2003; 76: 878-85. doi: 10.1016/S0003-4975(03)00555-1.
14. Giaccone G, Wilnik H, Paul MA, van der Valk P. Systemic treatment of malignant thymoma. Am J Clin Oncol 2006; 29: 336-344. doi: 10.1097/ 01.coc.0000227481.36109.e7.
15. Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008; 85 (2): 385-389. doi: 10.1016/ j.athoracsur.2007.08.051.
16. Haniuda M, Morimoto M, Nishimura H, et al. Adjuvant radiotherapy after complete resection of thymoma. Ann Thorac Surg 1992; 54: 311-315.
17. Loehrer PJ, Kim KM, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an Intergroup Trial. J Clin Oncol. 1994; 12: 1164-1168.
18. Fornasiesro A, Daniele O, Ghiotto C, et al.: Chemotherapy for invasive thymoma: A 13 year experience. Cancer 1991; 68:30-33. doi: 10.1002/ 1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4
19. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and Etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996; 14: 814-820.
20. Loehrer PJ, Jiroutek M, Aisner S, et al.: Combined Etoposide, ifosfamide and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. An Intergroup Trial. Cancer 2001; 91: 2010-2015. doi: 10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2
21. Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary Treatment for Advanced Invasive Thymoma with Cisplatin, Doxorubicin, and Methylprednisolone. J Thorac Oncol 2007; 2: 73-78. doi: 10.1097/ JTO.0b013e31802bafc8.
22. Lemma GL, Loehrer PJ, Lee JW, et al.: A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26 [Abstract 8018]
23. Hejna M, Haberl I, Raderer M. Nonsurgical management of malignant thymoma. Cancer 1999; 85: 1871-1884.
24. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993; 16(4):342-345. doi: 10.1097/00000421-199308000-00014.
25. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol. 2004; 130: 222-224. doi: 10.1007/s00432-004-0545-z.
26. Meister M, Schirmacher P, Dienemann H, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett. 2007; 248: 186-191. doi: 10.1016/ j.canlet.2006.07.003.
27. Nakagawa K, Matsuno Y, Kunitoh H, et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 2005; 128: 140-144. doi: 10.1378/chest.128.1.140.
28. Farina G, Garassino MC, Gambacorta M, et al. Response of thymoma to cetuximab. Lancet Oncol 2007; 8: 449-450. doi: 10.1016/ S1470-2045(07)70141-9.
29. Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007; 12: 757-761. doi: 10.2741/2098.
30. Kurup A, Burns M, Dropcho S, et al.: Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005, ASCO Annual Meeting Proceedings; 23: [Abstract 7068]
31. Bedano PM, Perkins S, Burns M, et al.: A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 19087]
32. Strobel P, Hautmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Eng J Med 2004; 350: 2625-2626. doi: 10.1056/NEJM200406173502523.
33. Giaccone G, Smit EF, van Groeningen C, Hogedoorn PC. Phase II study of imatinib in patients with WHO B3 and C thymomas. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 14665]
34. Salter JT, Lewis D, Yiannoutsos C, et al.: Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 8116]
35. Chuah C, Lim TH, Lim AST, et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006; 24: E56-e58. doi: 10.1200/ JCO.2006.08.8963.
36. Suster S, RoAai J: Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer 1991; 67: 1025-1032. doi: 10.1002/ 1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F
37. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: State of the art review. Int J Radiat Oncol Biol Phys 2004; 59: 654-664. doi: 10.1016/ j.ijrobp.2003.11.021.
38. Penzel R, Hoegel J, Schmitz W, et al. Clusters of chromosomal imbalances in thymic epithelial tumors are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003; 105: 494-498. doi: 10.1002/ijc.11101.
39. Inoue M, Starostik P, Zettl A, et al. Correlating genetic abnormalities with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003; 63: 3708-3715.
40. WeideLG, Ulbright TM, Loehrer PJ Sr, Williams SD: Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. Cancer 1993;71(4): 1219-1223. doi: 10.1002/ 1097-0142(19930215)71:4<1219::AID-CNCR2820710408>3.0.CO;2-B
41. Lucchi M, Mussi A, Basolo F, et al. The multimodality treatment of thymic carcinoma. Eur J Cardiothorac Surg 2001; 19: 566-569. doi: 10.1016/S1010-7940(01)00666-2.
42. Magois E, Guigay J, Blancard PS, et al. Multimodal treatment of thymic carcinoma: Report of nine cases. Lung Cancer 2008; 59: 126-132. doi: 10.1016/j.lungcan.2007.05.016.
43. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, et al. (2004) Multimodality therapy for thymic carcinoma (TCA) Results of a 30-year single-institution experience. Am J Clin Oncol 27: 68-72. doi: 10.1097/ 01.coc.0000046301.83671.09.
44. Huang J, Rizk N, Park B, et al.: Recent clinical experience with multimodality therapy in thymic carcinoma. J Clin Oncol 2007, ASCO Annual Meeting Proceedings; 25: [Abstract 18003]
45. Ciccone AM, Rendina EA. Treatment of Recurrent Thymic Tumors. Semin Thorac Cardiovasc Surg 2005; 17: 27-31. doi: 10.1053/ j.semtcvs.2004.12.004.
46. Loehrer PJ, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with Prednisone in Patients with Advanced Thymoma and Thymic Carcinoma. An Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22: 293-299. doi: 10.1200/JCO.2004.02.047.
47. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al.: A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2006, ASCO Annual Meeting Proceedings; 24: [Abstract 7079]
48. Umemura S, Segawa Y, Fujiwara K, et al. A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn J Clin Oncol 2002;32(7):262-265. doi: 10.1093/jjco/hyf059.
49. Oguri T, Achiwa H, Kato D, et al. Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 2004;50:279-282. doi: 10.1159/000082626.
50. Lucchi M, Basolo F, Mussi A. Surgical treatment of pleural recurrence from thymoma. Eur J Cardiothorac Surg 2008; 33: 707-711. doi: 10.1016/ j.ejcts.2008.01.015.
51. Sugie C, Shibamoto Y, Ikeya-Hashizuma C, et al. Invasive thymoma: postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination. J Thorac Oncol 2008; 3: 75-81. doi: 10.1097/JTO.0b013e31815e8b73.
52. DeBree E, van Ruth S, Baas P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121: 480-487. doi: 10.1378/chest.121.2.480.